December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

20.68 +1.90 (+10.12%)
Streaming Delayed Price Updated: 2:03 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
News headline image
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Government Stocks
News headline image
2 Mooning Stocks on Our Buy List and 1 Facing Challenges
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u... 
Via StockStory
Topics Initial Public Offering
News headline image
What's Happening With Novo Nordisk Stock Today? ↗
Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA‑approved GLP‑1 medications, including the... 
Via Benzinga
News headline image
Surging Oil Prices Spark Market Jitters ↗
The Motley Fool's Hidden Gems team discusses some historical disruptions in the energy market, how trends in semiconductors are reshaping the S&P 500, and why Hims & Hers stock is soaring. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
2 Healthcare Stocks to Target This Week and 1 That Underwhelm
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
This Hims & Hers Move Could Destroy Competitors ↗
The Wegovy pill could change Hims & Hers' growth in 2026. 
Via The Motley Fool
News headline image
Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up? ↗
The healthcare stock has lost more than half of its value in the past year. 
Via The Motley Fool
News headline image
1 Growth Stock with All-Star Potential and 2 That Underwhelm
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
Hims & Hers Opens Waitlist For $149 Branded Wegovy And Ozempic Via Novo Nordisk Deal ↗
Hims & Hers Health, Inc. (NYSE:HIMS) trended on Wednesday after the company outlined an expanded weight-management push tied to 
Via Benzinga
News headline image
Hims & Hers (HIMS) 2026 Deep Dive: The $1.15B Eucalyptus Deal and the Branded Pivot
As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year... 
Via Finterra
Topics Intellectual Property
News headline image
Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk ↗
The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform. 
Via Stocktwits
News headline image
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move ↗
These companies are benefiting from a tidal wave of demand for new weight-loss drugs. 
Via The Motley Fool
Topics Stocks
News headline image
Hims & Hers Health Stock Slips After Surging 50% In A Month ↗
Hims & Hers Health Inc (NYSE: HIMS) shares are pulling back Monday morning, giving back a portion of last week's sharp rally. 
Via Benzinga
News headline image
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks ↗
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending. 
Via The Motley Fool
MarketBeat Week in Review – 03/09 - 03/13 ↗
Despite continued volatility, stocks have stayed resilient as investors navigate the fog of war. The story is largely about oil. When the price of crude oil goes up, stocks go down and vice versa.... 
Via MarketBeat
News headline image
The Great Pivot: How the Novo Nordisk Deal Transformed Hims & Hers (HIMS) into a Healthcare Powerhouse
As of March 13, 2026, the healthcare landscape has witnessed one of the most significant pivots in the history of digital health. Hims & Hers Health, Inc. (NYSE: HIMS) has officially transitioned from... 
Via Finterra
Topics Economy
News headline image
Stock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit Taking ↗
On March 12, 2026, investors weighed profit-taking against a high-stakes pivot toward branded obesity drugs and telehealth growth. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Does This Deal Make Novo Nordisk Stock a Buy? ↗
Not many things have gone right for Novo Nordisk recently, but this is one of them. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
The New Era of Hims & Hers Health (HIMS): Navigating the Branded Obesity Drug Pivot
As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers... 
Via Finterra
News headline image
Why Hims & Hers Health (HIMS) Stock Is Surging In Thursday's Premarket ↗
HIMS stock jumps in Thursday premarket. Explore how the Novo Nordisk partnership and a 46% short float are driving Hims & Hers Health Inc (NYSE: HIMS) higher. 
Via Benzinga
News headline image
1 Value Stock with Exciting Potential and 2 We Ignore
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
These stocks are making the most noise in today's session. ↗
Via Chartmill
News headline image
Hims & Hers Stock Skyrockets as Landmark Settlement with Novo Nordisk Ends Weight-Loss Drug War
The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant... 
Via MarketMinute
Topics Economy Intellectual Property Lawsuit
News headline image
HIMS Stock Jumps 14% – Barclays Says Market Is Underestimating Opportunity From New Products ↗
Brokerages have turned bullish on HIMS since its deal with Novo Nordisk earlier this week, with Barclays raising the stock’s price target to $29. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Short Seller Who Bet Against Hims & Hers Now Says Its CEO 'Wiped The Floor' With Novo Nordisk ↗
Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents. 
Via Stocktwits
Topics Bankruptcy Fraud Intellectual Property
News headline image
3 Big Reasons to Love Hims & Hers Health (HIMS)
Hims & Hers Health has gotten torched over the last six months - since September 2025, its stock price has dropped 55.2% to $23.21 per share. This may have i... 
Via StockStory
News headline image
Asset Manager Exits Shares of Hims & Hers Health ↗
Hims & Hers Health has struggled, but it just inked a new partnership with Novo Nordisk. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal ↗
Via MarketBeat
News headline image
Disrupting the Pharmacy: A Deep-Dive into Hims & Hers Health (HIMS) in 2026
As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a... 
Via Finterra
Topics Artificial Intelligence Economy
News headline image
Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock ↗
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday. 
Via Stocktwits
Topics Intellectual Property Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.